0000899243-23-015636.txt : 20230615
0000899243-23-015636.hdr.sgml : 20230615
20230615180943
ACCESSION NUMBER: 0000899243-23-015636
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230613
FILED AS OF DATE: 20230615
DATE AS OF CHANGE: 20230615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Silver Brian M.
CENTRAL INDEX KEY: 0001860597
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40603
FILM NUMBER: 231018819
MAIL ADDRESS:
STREET 1: C/O TSCAN THERAPEUTICS, INC.
STREET 2: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TScan Therapeutics, Inc.
CENTRAL INDEX KEY: 0001783328
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 825282075
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 880 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 857-399-9500
MAIL ADDRESS:
STREET 1: 880 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-13
0
0001783328
TScan Therapeutics, Inc.
TCRX
0001860597
Silver Brian M.
C/O TSCAN THERAPEUTICS, INC.
830 WINTER STREET
WALTHAM
MA
02451
0
1
0
0
Chief Financial Officer
0
Stock Option (Right to Buy)
2.49
2023-06-13
4
A
0
632500
0.00
A
2033-06-12
Voting Common Stock
632500
632500
D
302,500 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 330,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023.
/s/ Brian M. Silver
2023-06-15